Naphazoline
Albalon, Nafazair, Naphcon, Naphcon-a, Opcon, Opcon-a, Vasocon, Vasocon-a, Visine (naphazoline) is a small molecule pharmaceutical. Naphazoline was first approved as Naphazoline hydrochloride on 1982-01-01. It is used to treat hyperemia, rhinitis, and sinusitis in the USA.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Combinations
Naphcon-a, Opcon-a, Visine (generic drugs available since 2010-09-27, discontinued: Vasocon-a)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Antazoline phosphate
+
Naphazoline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VASOCON-A | Novartis | N-018746 DISCN | 1994-07-11 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clear eyes cooling redness relief | OTC monograph final | 2023-06-12 |
| naphcon a | New Drug Application | 2022-06-22 |
| opcon-a | New Drug Application | 2020-03-11 |
| visine dry eye relief | OTC monograph final | 2023-01-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyperemia | EFO_0003822 | D006940 | H34.82 |
| rhinitis | EFO_0008521 | D012220 | J31 |
| sinusitis | EFO_0007486 | D012852 | J32 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AA: Sympathomimetics, plain
— R01AA08: Naphazoline
— R01AB: Sympathomimetics, combinations excl. corticosteroids
— R01AB02: Naphazoline
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01G: Decongestants and antiallergics
— S01GA: Sympathomimetics used as decongestants
— S01GA01: Naphazoline
— S01GA51: Naphazoline, combinations
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | — | 2 | 1 | — | 3 |
| Dry eye syndromes | D015352 | H04.12 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cold temperature | D003080 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fuchs' endothelial dystrophy | D005642 | EFO_0003946 | H18.51 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Hyperemia | D006940 | EFO_0003822 | H34.82 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NAPHAZOLINE |
| INN | naphazoline |
| Description | Naphazoline is a medicine used as a decongestant. It is a sympathomimetic agent with marked alpha adrenergic activity. It is a vasoconstrictor with a rapid action in reducing swelling when applied to mucous membrane. It acts on alpha-receptors in the arterioles of the conjunctiva to produce constriction, resulting in decreased congestion.
|
| Classification | Small molecule |
| Drug class | antihistamines/local vasoconstrictors (antazoline type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | c1ccc2c(CC3=NCCN3)cccc2c1 |
Identifiers
| PDB | — |
| CAS-ID | 835-31-4 |
| RxCUI | 7247 |
| ChEMBL ID | CHEMBL761 |
| ChEBI ID | — |
| PubChem CID | 4436 |
| DrugBank | DB06711 |
| UNII ID | H231GF11BV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 724 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,700 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more